(LLY.US) 1028 Daiwa: Lilly (LLY.US) oral weight loss drug clinical trial data shining, maintains target price of $1028.

Wisdom Financial APP learned that Morgan Stanley issued a research report stating that Eli Lilly (LLY.US) recently announced the results of its Phase III clinical trial (ATTAIN-1) for its oral GLP-1 receptor agonist Orforglipron (Orfor) for the treatment of obesity. The report pointed out that Orfor has shown excellent results in weight loss, improvement of cardiovascular metabolic indicators, and safety. The newly released data has not changed their positive outlook on the prospects of Orfor, and they maintain a "overweight" rating for Eli Lilly with a target price of $1028 in 12 months.